ライフサイエンスコーパス: day post

1 At 14 days post-AAA induction, radiotracer uptake by either gr

2 UMKO mice exhibited increased mortality 1-14 days post-AB.

3 re, or life-threatening bleeding (landmark 7 days post-ACS) and subsequent all-cause mortality was ev

4 pro-memory/proliferative cells in the early days post-activation.

5 ts in basal skin blood flow at 4 hours and 7 days post-administration were detected using laser Doppl

6 5 days post-administration, PAS800-IL-1Ra significantly re

7 ayed markedly extended blood plasma levels 3 days post-administration, whereas anakinra was undetecta

8 92 (17.42) days, compared with 12.35 (15.76) days post Affordable Care Act.

9 significantly higher lutein contents from 20 days post anthesis (dpa) but lutein esters were not dete

10 but fluctuated in the carpels from 10 to 30 days post-anthesis (DPA).

11 ke to M2-like phenotype within a mean of 3.5 days post antibiotics treatment, which is dependent on b

12 Test of cure was recommended 14-28 days post-antimicrobials.

13 rom individuals in late hibernation and four days post-arousal.

14 significantly later (median of 66 versus 42 days post-ART interruption, P < 0.01) and reached lower

15 and timing of CHB or sustained VT within 30 days post-ASA were assessed.

16 who used the CABANA monitors and provided 90-day post-blanking recordings qualified for this analysis

17 progenies were evaluated at 2, 5, 14, and 30 days post BrdU administration, with the use of selected

18 dorsal muscles were studied at 7, 14 and 21 days post-burn.

19 At 30 days post-CABG, 544 (68.4%) patients received DAPT and 2

20 Microglia were monitored at 2 and 10 days post-challenge by lipopolysaccharide.

21 usage, EBOTAb was first delivered 1, 2 or 3 days post-challenge with a lethal dose of EBOV.

22 gs look grossly and histologically normal at days post coitum (dpc) 6.5 and 7.5 of pregnancy.

23 meiotic differentiation of germ cells (13.5 days post coitum) and from both in vivo exposed mice and

24 At 3.5 days post-coitum (dpc) and 4.5 dpc, the tetraploid ESCs

25 onducted RNA-seq analysis of lungs from 18.5 days post-coitum (dpc) Src-1(-/-) /-2(-/-) (dKO) vs. WT

26 (dorsal aorta, umbilical, vitelline) of 9.5 days post coitus (dpc) to 11.5 dpc mouse embryos by sing

27 ing systemic antibiotics and continued for 5 days post completion of systemic antibiotics [OVP]), or

28 Test of cure (TOC) was recommended 14-28 days post-completion of antimicrobials.

29 s underwent neurobehavioral evaluation on 32 days post conception and then were transcardially perfus

30 coping styles showed equal memory recall one day post-conditioning, reactive zebrafish showed signifi

31 oned context relative to proactive fish four days post-conditioning.

32 At 2 days post-contact, SARS-CoV-2 was detected in all naive

33 umors were imaged by MRI at baseline and 2-3 days post-crolibulin (13-24 mg/m(2)).

34 analyzed motoneurons during regeneration (21 days post crush) and after they reinnervate muscle (3 mo

35 mples for their menstrual cycle and up to 28 days post day of missed period.

36 ight(3%) of whom were discharged prior to 28-days post decision to intervene surgically.

37 predicted provisional PTSD diagnosis 90-180 days post deployment (random forest: AUC = 0.78, 95% CI

38 ar two at large, with detections up to ~1700 days post deployment.

39 non-small cell lung cancer followed from 30 days post-diagnosis in English secondary care were obtai

40 nt RRD patients received treatment within 60 days post-diagnosis.

41 Risk-adjusted 30-day post-discharge mortality declined from 7.1% in 2006

42 ates also declined from 2006 to 2017 with 30-day post-discharge mortality from 5.1% to 4.4%.

43 here was no discontinuity in mortality at 30 days post-discharge, or for either outcome at hospitals

44 the intervention on functional status at 90 days post-discharge.

45 g an opioid prescription between 91- and 180-days post-discharge.

46 with an increased likelihood of death at 30 days post-discharge.

47 S geometric mean concentrations (GMCs) 30/60 days post-dose 2 in previously GBS-vaccinated women were

48 ry threshold of 8 ug/mL for each serotype 60 days post-dose 2, versus 36%-56% post-dose 1 in previous

49 ced humoral and cellular immune responses 21 days post-dose 2; responses were higher following hetero

50 ZV-specific immune response approximately 28 days post-dose 4, measured by gpELISA (estimated geometr

51 ety and tolerability was assessed through 28 days post-dose 4.

52 d by gpELISA or ELISPOT, at approximately 28 days post-dose 4.

53 administration, with peak concentrations 1-6 days post-dose.

54 m the last day of lactation to 3, 10, and 21 days post dry-off.

55 Duration of SNHL (60 versus 90 days post DT injection) had no effect on RAM performance

56 ctively restore memory at all ages, from one-day post-eclosion to thirty-day-old flies, proving their

57 JH titers during the sensitive period (first day post-emergence) regulates the shift from migrants to

58 g a sensitive period in adulthood (the first day post-emergence), but the role of JH in this switch i

59 Mice were treated 13 days post-engraftment with an intravenous injection of (

60 th delirium-/coma-free days by 1 week and 30 days post enrollment.

61 es and excitatory postsynaptic currents at 3 days post-exercise, indicative of exercise-induced struc

62 ed to Ebola virus (EBOV) disease from 5 to 8 days post exposure.

63 p to 72 h, and mortality was monitored for 7 days post exposure.

64 y analysing the head-thorax and saliva at 13 days post-exposure to birds.

65 ring the clinically latent period and at 180 days post-exposure to irradiation.

66 lipids (-49.7%) compared to controls at nine days post-exposure.

67 etectable plasma viremia in all animals by 2 days post-exposure; virus replication kinetics are simil

68 roup than in estrogen-sufficient group at 30 days post-extraction (P < 0.05).

69 lower BH than all other groups at 20 and 30 days post-extraction (P < 0.05).

70 Rats were euthanized at 10, 20, and 30 days post-extractions.

71 The 14-day post-feeding mortality for mosquitoes fed 7 days pos

72 Mosquito survival was assessed daily for 28 days post-feeding.

73 eters in post-hatching larvae of 3, 4, and 5 days post fertilisation (dpf).

74 pment across 18 time points from 1 cell to 5 days post-fertilisation sampling individual and pools of

75 ed, axenic, and axenic larvae colonized at 1 day post fertilization (dpf) were evaluated using a stan

76 This approach relies on use of 2-day post fertilization wild-type embryos, and uses only

77 s in homozygous mutant embryos starting at 3 days post fertilization (dpf) that result in lethality b

78 f head structures and are not viable past 10 days post fertilization (dpf).

79 tion locomotor response (LMR) test in 4 to 5 days post fertilization zebrafish with respect to differ

80 aptic transmission, survive until ~10 d dpf (days post fertilization), providing a unique opportunity

81 lization with elevated autophagy levels at 6 days post fertilization, indicating a more severe genoty

82 al lethal, with no mutants surviving past 13 days post fertilization.

83 n-teratogenic E2 concentrations from 1 to 10 days post-fertilization (dpf).

84 hysiological signs of seizure activity by 10 days post-fertilization and early death by 16 days post-

85 81 live, intact zebrafish embryos at 2 and 5 days post-fertilization highlighted genes that influence

86 sh model for ACR neurotoxicity by exposing 5 days post-fertilization zebrafish larvae to 1 mM ACR for

87 on of 35% and 90% of cloned genes at 2 and 4 days post-fertilization, respectively.

88 pendent higher HRV and lower heart rate at 5 days post-fertilization.

89 ree developmental time points-80, 87 and 117 days post-fertilization.

90 quential time points ranging from 6.5 to 8.5 days post-fertilization.

91 ays post-fertilization and early death by 16 days post-fertilization.

92 n of a larval zebrafish (Danio rerio) at 5.5 days post-fertilization.

93 453 single nuclei from mouse embryos at 8.25 days post-fertilization.

94 These T-cells peaked at 11 days post-H1N1 infection, and were strongly induced in b

95 F1 generation were exposed to EDCs until 21 days post hatch (dph), reared to adulthood in clean wate

96 patients, gadolinium contrast resolved by 60 days post-HCT.

97 Three days post-I/R, dual isotope imaging was performed with (

98 ignificantly slower lymphatic drainage for 6 days post-ICG injection (P < 0.05).

99 patients at the late convalescent phase (30 days post-illness).

100 the tears of infected patients for up to 30 days post-illness, and may therefore possess a potential

101 in stool collected on alternate days for 10 days post-immunization.

102 wed effective relief of pain for more than 4 days post-implantation and efficacious local etoricoxib

103 on-perfusable self-assembled constructs at 5 days post-implantation.

104 d from spleen tissues taken at 10-day and 21-day post infection (dpi).

105 prior to YHV infection had 50% survival at 8 day-post infection (dpi), whereas 84.1% mortality was ob

106 eproductive tissues were harvested 14 and 35 days post infection (DPI) for inoculation studies and 14

107 he eIF2 family was evaluated at two- and six-days post infection (dpi) in the spleen from both lines,

108 Ranavirus was first detected at 3 days post infection (p.i.) in the oral cavity and upper

109 tal challenge (day 0) and at 4, 7, 11 and 14 days post infection from 44 pigs revealed 6,430 differen

110 alkaloids between the orange layers after 4 days post infection in concentrations > LOQ.

111 After 8 days post infection, Il10(-/-) mice infected with Cj-P1

112 35 days post infection, mice were treated with low dose hyd

113 icated the in vivo antiviral host response 7 days post infection, with no induction of interferon-sti

114 only from animals euthanized on or before 15 days post infection.

115 EBOV and SUDV infection when delivered four days post infection.

116 these were not statistically different at 18 days post-infection compared to uninfected animals indic

117 ly, a single dose of WNV-86 administered two days post-infection protected mice from lethal WNV chall

118 ealed peak infection density in gut at 10-12 days post-infection when blood viral loads were low.

119 acute vs. early chronic infection (7 vs. 28 days post-infection), using neurological and behavioral

120 en rhesus monkeys euthanized between 3 and 8 days post-infection, and 3 uninfected controls were enro

121 en 7 days prior to infection and 3, 6 and 14 days post-infection, and blood samples 4 days prior to i

122 us received cART beginning between 4- and 27 days post-infection, leading to the establishment of dif

123 6 spores unable to transmit malaria within 5 days post-infection, surpassing the World Health Organiz

124 cells were not readily detectable by ET at 5-days post-infection, whereas HIV-1-infected cells surrou

125 sal washes, saliva, urine, and feces up to 8 days post-infection.

126 , with survival recorded from three to seven days post-infection.

127 to their colonies and sampled 5, 10, and 21 days post-infection.

128 infested and uninfested control plants at 10 days post infestation.

129 14.5) and 14-20 (mOR: 2.5, 95% CI: 1.1, 5.5) days post influenza infection.

130 ation and antidepressant response at 3 and 7 days post-infusion.

131 40, 80, 120, and 230 min and at 1, 2, and 3 days post-infusion.

132 eturn for at least one PrEP refill within 45 days post initiation) was strongly associated with repor

133 as very long with still 66% remained on 12th day post injection.

134 Spleen samples were collected at 40 days post injection (dpi), and sequenced.

135 and Val showed the greatest difference at 16 days post injection for both Dox penetration and retenti

136 ates in rhythmically expressed genes up to 2 days post injection, and in all expressed genes, we see

137 growth and a 27.69% increase in necrosis 20 days post-injection compared to Dox alone ISFIs.

138 - to 10-fold overexpression of NT3 from 1-21 days post-injection, and 1.7-fold overexpression at 40 d

139 -fold increase in drug retention at 5- and 8-days post-injection, respectively, compared to ISFIs wit

140 Although beta cell mass was preserved 8 days post-injection, total insulin content and insulin:c

141 ose (MTD) of the particles was determined 10 days post-injection.

142 of each conjugate per mouse) at 1, 7 and 13 days post-injection.

143 were efficiently cleared from the host by 20 days post-injection.

144 ary objective was safety and tolerability 28 days post-injection.

145 oxorubicin followed by LSFI at 3, 30, and 60 days post-injection.

146 signals from Cy5.5-CTLs at tumors after 2-3 days post-injection.

147 Microvascular perfusion ceased within 1 day post injury and was restored at 5 days coincident wi

148 Overall miRNA expression at 1 and 3 days post injury strongly correlates with outcome measur

149 4 h post injury and who had an MRI scan 7-18 days post injury.

150 At 3 days post-injury (dpi), decreased expression of genes as

151 boron, was administered for 7 days, p.o., 21 days post-injury at a dose level of 4 mg/kg body weight.

152 s in the penumbra of 49% at 14 and 40% at 28 days post-injury compared to animals treated with the ve

153 TBI + Sp mice infected 60 days post-injury had a 60% mortality compared with 5% mo

154 ry cortex of microglia-depleted animals at 7 days post-injury remained unchanged compared to contrala

155 ce network was evaluated at 5, 10, 21 and 35 days post-injury vs. Control by measuring internal diame

156 At 3 days post-injury, S. pneumoniae-infected traumatic brain

157 the cortex and/or hippocampus at 1 and/or 21 days post-injury.

158 the 0-day time point that persisted until 90 days post-injury.

159 hicle (phosphate-buffered saline) at 3 or 60 days post-injury.

160 on leaf samples collected at 0, 1, 3, and 8 days post inoculation (DPI).

161 Beginning 4 or 5 days post inoculation, cynomolgus macaques were treated

162 us disease model with treatment initiation 5 days post inoculation, supporting further assessment of

163 Additionally, feces were collected for seven days post-inoculation to determine the effect on gut bac

164 ralis mixed with S. intermedius (P < 10-6) 7 days post-inoculation.

165 eola, and pathogenicity level was recorded 4-days-post-inoculation.

166 r spontaneous vaginal deliveries (SVD) and 3 days post instrumental vaginal deliveries (IVD).

167 rity and mature blood cell recovery at 21-30 days post-irradiation.

168 ation mitigated brain micro-hemorrhage at 21 days post-irradiation.

169 eostomy takedown occurred at a median of 422 days post-ITx.

170 ic resonance imaging (rsfMRI) was acquired 2 days post-ketamine (final sample: TRD n = 27, HV n = 19)

171 ot remain markedly elevated beyond the first day post-KT.

172 ne expression were maintained for at least 5 days post-KT.

173 exhibited a greater coagulation activation 7 days post-LAAC (P=0.038 and P=0.108 for F1+2 and TAT, re

174 ntly reduced coagulation activation within 7 days post-LAAC compared with APT (23% [95% CI, 5%-41%] v

175 vere infections remain effective up to three days post lethal inoculation, our approach may successfu

176 Mice were sacrificed at 5, 9, 14, 28, and 56 days post-loading and whole knee joint changes were asse

177 lial cell basolateral secretions (1, 2 and 3 days post-loading), but not apical secretions, suppresse

178 with nearly a two-fold increased risk for 30-day post-LT mortality (adjusted HR, 1.89, 95% CI: 1.30-2

179 ariable (D-MELD 0-4, 5-10, >10) on early, 30-day post-LT mortality was assessed.

180 CI: 1.04-1.10) was associated with higher 30-day post-LT mortality.

181 en patients are alive after an average of 30 days post-LT (range 3-46).

182 ne (CsA) levels obtained during the first 15 days post-LT were collected.

183 nas invaded the host microbiota within three days post-LT, in association with a reduction in richnes

184 IPV was estimated during the first 15 days post-LT.

185 muscle index, there was a 4% decrease in 30-day post-LVAD sCr (95% CI, 1%-6%, P=0.004).

186 hest computed tomography performed within 40 days post-LVAD were studied.

187 In retrospective cohort, for every 5 days post-LVAD, a 6% decrease in pectoralis muscle index

188 ase) inhibitor dichloroacetate was started 7 days post-MCT.

189 rved a linear relationship between T (req) 2 days post-MI and global longitudinal strain 6 months lat

190 EF at the time of MI and within 180 days post-MI were determined from all available medical

191 , and smaller scar size than control mice 28 days post-MI.

192 ncreased the expression of Mmp14 (MT1-MMP) 7 days post-MI.

193 At 28 days post-myocardial infarction, exosomes derived from n

194 s and altered pattern of HSPC mobilisation 8 days post-myocardial infarction, with increased circulat

195 sociated with reduced myocardial fibrosis 28 days post-myocardial ischemia-reperfusion injury.

196 We calculated neonatal (age 0-27 days), post-neonatal (age 28-364 days), child (age 1-4 y

197 er noise exposure in the Foxo3KO/KO fourteen days post noise (DPN).

198 re obesity; and (2) utilization rates and 30-day post-operative outcomes.

199 Studies reporting the primary endpoint, 30-day post-operative stroke rate, were included in a Bayes

200 who received an ACE inhibitor/ARB within 30 days post-operatively had a 57% reduction in the risk of

201 tor/ARB exposure status was landmarked at 30 days post-operatively to avoid immortal time bias.

202 Flap biopsies were performed 3 and 7 days post-operatively, and the specimens submitted to im

203 hienopyridine) and aspirin monotherapy at 30 days post-operatively.

204 e 60 muL serum aliquots of blood collected 4 days post-oral exposure.

205 um ranelate were administrated from the 14th day post-ovariectomy/sham surgery until euthanasia.

206 estation, and at the post-partum visit (0-14 days post partum).

207 death after 16 weeks' gestation and before 7 days post partum; 0.86 [0.74-1.00], p=0.039), early pret

208 a peripheral vein on the same day and second day post-partum.

209 s, or >=1.5-fold relative elevation within 7 days post-PCI from the reference value ascertained withi

210 iac magnetic resonance imaging measured at 2 days post-PCI showed no difference between the postcondi

211 varied substantially across sites in the 30 days post-PCI.

212 s, respectively, with sampling times 0 to 56 days post-positive PCR (median/mean, 2/6.2 days).

213 itation severity by at least one grade at 30 days post procedure, with a performance goal of 35%, ana

214 observed hospital mortality was 7.2%, and 30-day post-procedure mortality was 8.5%.

215 However, 30-day post-procedure pacemaker insertion increased from 8.

216 SSIs within 90 days post-procedure were identified; infections during a

217 of scores on the modified Rankin Scale at 90 days post-randomisation.

218 etrovirally labeled new granule cells at 7-8 days post retroviral injection (dpi) show that these cel

219 At 30-days post-revascularization, for ACS patients the odds r

220 duction in spatial learning and memory at 24 days post-rmTBI compared to repeated sham (rSham) injury

221 ume in 1 second decline >=5% and >=10% at 90 days post-RSV infection had a higher 1-year mortality (P

222 At 3 days post S. aureus infection, bacterial burden in lungs

223 carriage is measured in a treated group, 14 days post-Salmonella challenge.

224 decrease in myelin phagocytosis in mice at 7 days post-SCI.

225 e determined 7 +/- 1, 14 +/- 2, and 21 +/- 2 days post-sclerotherapy, respectively.

226 The early transient (3 days) post-SE infusion of bumetanide reduced rMF sprouti

227 In timeframes beginning 30 days post-second dose, the primary endpoint (overall vac

228 At 14 days post-SH, the proportion of animals displaying recov

229 ve ART within 48 h (urgent group) or in 7-14 days (post-stabilisation group) at four hospitals in Ken

230 ascular thrombectomy improves outcomes at 90 days post stroke.

231 at baseline and having AF first diagnosed >7 days post-stroke (late AF) was highly associated with re

232 IS, determine their temporal course up to 90 days post-stroke, and explore their utility as an early

233 in cognitive functioning between 90 and 365 days post-stroke.

234 formation and non-leaky blood vessels by 10 days post-stroke.

235 the effect of RRT on ammonia for the first 3 days post study admission (n = 340) and on 21-day TFS (n

236 Sixty days post-surgery (baseline), subjects were randomized i

237 Five days post-surgery, sympathetic nerve density was reduced

238 so resulted in significantly reduced pain 14 days post-surgery.

239 In modern day post-surgical care, VTE remains a significant occurr

240 eronegative slightly increased from 14 to 90 days post symptom onset (p=0.06).

241 PCR, serological sensitivity increased with days post symptom onset with >50% of patients seropositi

242 Clinical sensitivity of PCR decreased with days post symptom onset with >90% clinical sensitivity d

243 91.2% (95% CI, 81.8%-96.7%) for samples >14 days post symptom onset, with specificity 94.4% (95% CI,

244 93.8% (95% CI, 85.0%-98.3%) for samples >14 days post symptom onset.

245 atively stable among persons tested up to 90 days post symptom onset.

246 PCR)-confirmed COVID-19 cases sampled at >14 days post-symptom onset (DPSO), whereas the salivary ant

247 version of both IgG and IgM occurs around 12 days post-symptom onset (range 1-40), with extensive ind

248 t-phase serum samples collected more than 14 days post-symptom onset or post-initial positive reverse

249 ncreasing by 39% (CH) until HF developed 150 days post-TAC when FS decreased from 70% to 39%.

250 nd perinuclear versus cytosolic regions at 5 days post-TAC.

251 Improvement in DD grade/grade 1 DD at 30 days post-TAVR was seen in 70.8% patients.

252 nd points including neurological events <=30 days post-TAVR were collected for all patients who under

253 ts (7.1%) experienced late readmissions (>30 days post-TAVR), and 17 (2.3%) had multiple readmissions

254 ed with 30-day AEM to assess for DH-AVB (>=2 days post-TAVR).

255 d H-AVB necessitating permanent pacemaker <2 days post-TAVR, 1 died pre-discharge, and 13 declined AE

256 h post-TAVR eGFR, change in CKD stage at <=7 days post-TAVR, and association of post-TAVR eGFR on int

257 red in 1 (0.035%) of 2,892 patients within 7 days post-TAVR.

258 al cohort) a median of 6 days (range 3 to 24 days) post-TAVR.

259 ng perfusion to label the entire cortex at 1 day post TBI followed by whole brain axial and coronal i

260 r 72 h post-TBI) or double doses (48 h and 5 days post-TBI) subcutaneous (SC) injection increased 30-

261 red early (within 1 week) and late (up to 90 days post-TBI).

262 n regions of pathology in lungs of mice at 7 days post-TDM introduction.

263 -GFP and pUB-GFP plasmids and for at least 5 days post-transfection for cells transfected with pEYFP-

264 heir blood urea nitrogen was elevated at two days post-transfer but resolved within two weeks.

265 series of three heart transplants at a five-day post-transplant endpoint.

266 dney recipients with functional grafts at 90 days post-transplant were followed prospectively for a m

267 nsplantation and continuing weekly until 100 days post-transplant, a total of 694 observations in HCT

268 s sustained, miR-21 was measured daily for 5 days post-transplant, and was consistently elevated in t

269 npatient antibiotic use was examined for 100 days post-transplant.

270 78 (99%) of 79 patients had survived at 30 days post-transplant.

271 3 patients developed HS a median of 7 days post-transplant; 2 died of HS.

272 to 2020 (94%) patients during the first 100 days post-transplant; average antibiotic exposure was 41

273 At 10 days post-transplantation, hUC-MSC sheets remain on ecto

274 donor-specific, antibody-positive ABMR >=365 days post-transplantation.

275 ess (caused by corneal oedema) occurred at 1-day post-treatment but resolved in the majority of cases

276 urring in rice roots during NLS formation, 7 days post-treatment (dpt) with auxin, 2,4-D.

277 Lithium concentrations peaked three days post-treatment in both larvae and honey and increas

278 post-feeding mortality for mosquitoes fed 7 days post-treatment on blood from pooled patients in bot

279 to kill Anopheles mosquitoes for at least 28 days post-treatment when fed patients' venous blood usin

280 l swelling and decreased tumor perfusion 2-3 days post-treatment with crolibulin.

281 shallow and deep sites, at baseline or at 90-days post-treatment, and the microbiome of both site cat

282 d C3 on peritoneal tumor cells as early as 5 days post-treatment.

283 ific for M. genitalium DNA on samples 14-100 days post-treatment.

284 re individually collected at baseline and 90 days post-treatment.

285 -induced eosinophilia persisted for up to 20 days post-treatment.

286 nosis, and at 1-14 days, 14-31 days, and >31 days post-treatment.

287 l; OR 0.56; 95% CI, 0.36-0.88, P = .01 at 14 days post-treatment; 1 trial).

288 ps (OR 0.06; 95% CI, 0.00-0.47, P < .01 at 7 days post-treatment; 1 trial; OR 0.56; 95% CI, 0.36-0.88

289 In the 7 days post vaccination, 60 (94%) of 64 intradermally vacc

290 We report that LAIV induced early (3-7 days post-vaccination) activation of tonsillar follicles

291 ronchoalveolar lavage (BAL) were performed 7 days post-vaccination.

292 tiplex immunoassay pre-vaccination and 30/60 days post-vaccination.

293 d stool viral shedding was assessed up to 28 days post-vaccination.

294 ondary objectives were assessed for up to 60 days post-vaccination.

295 hin 10 days, and persisted until at least 35 days post-vaccination.

296 s, and ARPE-19 retinal epithelial cells at 4 days post-VZV infection.

297 , and colon were collected approximately 164 days post-weaning at the time of slaughter.

298 ies that presented within each sample at 180 days post whole-thorax lung irradiation.

299 al extracellular matrix (ECM) formation by 3 days post-wounding.

300 ative of a compromised blood-brain barrier 3 days post-ZIKV exposure.